Winning The Battle From HIV-1: (MPTV-x , HAART-x) / (MPTV-x , Mega-HAART-x) – Couples Produced of a Multivalent-Polivalent-Therapeutic-Vaccine (MPTV-x) and Its Corresponding HAART-x , and also Mega-HAART- Regimen , Respectively. Iosif Secasan Department associated with Urologic Surgery Spitalul Judetean Resita / The Hospital involving Resita RO-1700, Resita Dan I. Pop Facts International SRL Str. Horia, Nr.6, Bl.6, Et.Twelve, Ap.39 Resita-1700, RO-1700, Romania Phone: 0040-722-940299 E-mail : danpop77@yahoo.org Ciprian C. Secasan Department of Microbiology Or Department of Urologic Surgery Spitalul Judetean Resita Per The Hospital of Resita RO-1700, Resita Abstract : This short article presents, for the first time in Health, an entirely new theory and practical solution to eradicate HIV-1, dependant on HIV-1′s ability and need to mutate under HAART-x / Mega-HAART-x drugs pressure, and also on the sinergetical scissoring effect on HIV-1 of (MPTV -x , HAART-x) : couples and (MPTV-x , Mega-HAART-x)-couples, which are formed of : 1. a multivalent-polyvalent-therapeutic-vaccine (MPTV -x) , created from whole-killed HIV-1 (or of particular regions of HIV-1) bearing on its genome (biochemical structure) a resistance-mutations-pattern (RMP-x) that would be induced by the next , to come HAART-x or Mega-HAART-x regimen as well as 2. the respective, matching HAART-x or Mega-HAART-x regimen, respectively. Key Words : HAART (highly-active-anti-retroviral-therapy), HAART-x regimen, Mega-HAART-x regimen, point-mutations (PM), resistance-mutations-loci (RML-x), resistance-mutations-sites (RMS-x), resistance-mutations-pattern (RMP-x-), multivalent-polyvalent-therapeutic-vaccine (MPTV -x), (MPTV -x, HAART-x)-couples, (MPTV-x,Mega-HAART-x)-couples, drug-resistant-virus(DRV) , drug-sensitive-virus (DSV); Release: Time has come for Scientific disciplines and Medicine to win the battle against Human immunodeficiency virus and AIDS. This article reveals, for the first time in Medical History, an entirely new theory and functional solution to eradicate HIV-1, based on HIV-1′s potential and need to mutate under HAART-x Or Mega-HAART-x drugs pressure, and on the particular sinergetical scissoring effect on HIV-1 of (MPTV -x ,HAART-x) – lovers and (MPTV-x , Mega-HAART-x)-couples. Since a common vaccine against HIV-1 is hard to design as well as define, and since current HAART (highly-active-anti-retroviral-therapy) and even Mega-HAART regimens are unable to clear the HIV-1 infection , a combined strategy has to be adopted, in order to achieve HIV-1 eradication. This article presents an entirely fresh theory and practical answer to eradicate the HIV-1 virus on the body of HIV-1 infected person’s, by combining HAART (or Mega-HAART) by using a multivalent-polivalent -therapeutic-vaccine (MPTV), pre-administrated to HAART, (or Mega-HAART respectively) in addition to targeted against the in-advance-known resistance-mutations-sites (RMS) / resistance-mutations-loci (RML) And point mutations(PM) or simply against entire resistance-mutations-pattern(s) (RMP-s) of the following , to come HAART or Mega-HAART strategy, respectively. The polivalent, multivalent, or multivalent-polivalent therapeutic vaccine (PTV-x, MTV-x, MPTV-x) made of killed/highly inactivated HIV-1, bearing on its genome blueprint the resistance-mutations-loci (RML-x)/resistance-mutations-sites (RMS-x), the point-mutations(PM-x), or the entire resistance-mutations-pattern (RMP-x) that would be generated by the subsequent , to come , HAART-x , is pre- administrated to HAART-x, plus forms a couple with it : (MPTV -x, HAART-x) as well as (MPTV-x, Mega-HAART-x) , respectively. A series, or repetitive cycles of (MPTV -x, HAART-x) couples, every couple encompassing a multivalent-polivalent-therapeutic-vaccine (MPTV -x) qualified against/ or encoding /or containing /the inside – advance – identified resistance-mutations-loci (RML-x) / resistance-mutations-sites (RMS-x) , point-mutations(PM-x), or the whole resistance-mutations-pattern (RMP-x) on the following, to come HAART-x – schedule (or Mega-HAART-x -regimen , respectively) may lead to this eradication of HIV-1 from the system of a HIV-1 positive person. The development of such a successful HIV-1 eradication treatments may save all 40-50 thousand persons who are HIV-infected worldwide and would solve the HIV/AIDS problems. Materials and Methods : The general HIV-1 reduction scheme in a series and/or multi-cycle circumstances is : (MPTV-1, HAART-1), —-.> (MPTV-2, HAART-2), —-> (MPTV-3,HAART-3),—->……..(MPTV-x, HAART-x)……..—->(MPTV-n, HAART-n) —–> —>(MPTV-1M, Mega-HAART-1),—->( MPTV-2M, Mega-HAART-2), —->(MPTV-3M, Mega-HAART-3)—->….( MPTV-xM, Mega-HAART-x), ….—->(MPTV-nM, Mega-HAART-n)—> —–> Eradication clearly implying that each multivalent, polivalent, or multivalent-polivalent-therapeutic-vaccine (MPTV-x) is pre-administrated so that you can / (precedes) its corresponding HAART-x – regimen (or Mega-HAART-x ( blank ) regimen respectively), and is aimed against ( or encodes/or contains) the in -advance-known resistance-mutations-loci (RML-x) / resistance-mutations-sites (RMS-x), point-mutations(PM-x), or even the full resistance-mutations-pattern (RMP-x) that would be generated by the subsequent , to come HAART-x – regimen (or perhaps Mega-HAART-x-regimen, respectively) on HIV-1′s genome blueprint. Quite simply, MPTV-x is preventing the victory of HAART-x – resistant * virus, acting in fact such as a typical VACCINE against the HIV-1 virus that is going to otherwise emerge after HAART-x treatment. While MPTV-x is preventing this emergence of HAART-x – immune – virus, HAART-x is decreasing viral load, i.age. the numbers of drug-sensitive- virus (DSV). The synergetic scissoring consequence of a (MPTV-x,HAART-x) -couple on HIV-1 may be Thousands of or even 10.000 times (3-4 Log) more effective and effective than any current HAART-x ( space ) regimen given alone, particularly terms of reducing HIV-1 viral insert. Considering that a typical HAART-x regimen is currently able to reduce HIV-1 viral load from 60.000 copies/ml or more, to 20 copies/ml or lower, some sort of (MPTV-x, HAART-x)-couple might be able to reduce viral lots from 60.000 copies/ml or maybe more to 2-20 copies/litre, whereas a succession of different (MPTV-x, HAART-x)-couples, may lead to eradication connected with HIV-1 from the body of HIV-1 beneficial persons. In order to better reflect the potential anti-HIV-1 power of partners formed by a multivalent-polivalent therapeutic vaccine (MPTV-x) and its particular corresponding HAART-x – regimen , it is usually estimated that a single antiretroviral medicine like AZT, (or e.f. Crixivan) , would be as effective while 3-4 antiretroviral drugs ( i.e. seeing that effective as HAART ), provided that it’s preceded by a multivalent-polivalent-therapeutic-vaccine (MPTV-x) containing wiped out HIV-1 (or particular parts of HIV-1) referring to its genome (biochemical structure) the resistance-mutations-pattern(RMP) associated with AZT. Figure1/Table1 presents the RMS/RML for different antiretroviral drugs as well as for 2 drug combinations, i actually.e. their ” point-mutations”. The particular “point-mutations” induced by a particular drug form/build your resistance-mutations-pattern(RMP) of HIV-1 to that drug. Figure1/Table1 Medication Class Primary Resistance Strains Mutations With Additional Effect RTIs AZT (Retrovir®) M41L, T215Y, T215H D67N, K70R, K219Q, K219E 3TC (Epivir®) M184V, M184T, M184I ddI (Videx®) L74V K65R, L74V, V75T, M184V ddC (HIVID) K65R T69D, L74V, V75T, MI84V, Y215C Abacavir (Ziagen) K65R, L74V, Y115F, M184V D4T (Zerit®) V75T 150T PFA E89G, E89K, L921 W88G, W88S, S156A, Q161L, H208Y NNRTIs Nevirapine (Viramune®) K103N, Y181C, Y181I A98G, L100I, V106A, V108I, Y188C, G190A Delavirdine (Rescriptor®) K103N, K103T, Y181C P23L Efavirenz (Sustiva) Y188L L100I, K101E, K103N, V108I, V179D, Y181C Protease Inhibitors Indinavir (Crixivan®) M46I, M46L, V82A, I84V L10I, L10R, K20M, K20R, L24I, V32I, I54V, A71V, A71T, L90M Nelfinavir (Viracept®) D30N, M46I, A71V, I84V M36I, V77I, N88D, L90M Saquinavir (Fortavase®) G48V, L90M L10I, I54V, I84V Ritonavir (Norvir®) V82A, V82F, V82S, I84V K20R, L33F, M46I, I54L, I54V, A71T, A71V, L90M Effectiveness against Multiple Drugs AZT + ddI/ddC A62V, V75I, F77L, F116Y Q151M (all 4 mutations required for significant amount of resistance) AZT + 3TC M184V + R211K + L214F G333D, G333E A large database containing most published HIV-1 reverse-transcriptase and protease sequences, which allows for mutations searching is found at : http://hivdb.stanford.edu/ HIV-1 recombination and mutation (1-6), including “resistance-mutation”, are needed mechanisms by which HIV-1 evades drug or perhaps immune pressures. HIV-1- strains which can be resistant to an antiretroviral drug existing multiple ” point-mutations”(PM), which often act in synergy to confer the resistant phenotype to that particular drug, and we may outline these “point-mutations” (PM-x) as resistance-mutations-loci (RML-x) or resistance-mutations-sites (RMS-x), whilst their ensemble may be named resistance-mutations-pattern (RMP-x). Multidrug resistant HIV-1 strains arise in patients treated with HAART-x or Mega-HAART-x, through direct mutation or through recombination associated with variants that are resistant to sole drugs. Paradoxically, and luckily concurrently, point-mutations (PM) that confer pharmaceutical – resistance offer people targets for vaccine(s) and particularly for therapeutic vaccines(TV-s) development. The drug-induced point-mutations (PM), or resistance-mutations-loci (RML-x)/resistance-mutations-sites (RMSx), or use the entire resistance-mutations-patterns (RMP-x-s) may be contained/encoded/encompassed in a multivalent, polivalent as well as multivalent-polivalent-therapeutic-vaccine (MPTV-x) aimed to prevent the victory of HAART-x – resistant HIV-1 trojan. In HIV-1 infection, the inflammed hosts apparently cannot clear up the problem of identifying a antigen that is conserved among the different versions and quasispecies, and thereby neutralize the infection. Paradoxically and luckily once more, both HAART and Mega-HAART regimens are not just reducing HIV-1 viral loads for you to 50 copies/ml or less, however are also UNIFYING HIV-1′s diversity, by “artificially” developing a common factor among the remaining/surviving 55 copies/ml of drug-resistant-virus(DRV), in form of resistance-mutations-loci (RML-x) resistance-mutations-sites (RMS-x) or point-mutations (PM), which in concert build the resistance-mutations-pattern (RMP-x). Each point-mutation (PM) taken separately, and even total resistance-mutations-patterns (RMP-x-s) are both excellent targets with regard to therapeutic vaccines (TV), possibly at the same time can be used as a easy, or polyvalent, or multivalent, or multivalent-polyvalent -therapeutic- vaccines (MPTV -x) respectively, namely in sort of whole-killed or highly – inactivated HIV-1 malware (Remune-like and/or Remune- modified bearing the HAART-x or maybe Mega-HAART-x mutations ) , bearing on its genome strategy the resistance-mutations-pattern(s) (RMP-x-s) of the right after , next , to come HAART-x or Mega-HAART-x : regimen. Interestingly and significant, within each (MPTV -x, HAART-x)-couple, and by analogy within each (MPTV-x,Mega-HAART-x)-couple, the multivalent-polyvalent remedial vaccine (MPTV -x) acts in fact like a real vaccine, like a CLASSICAL VACCINE against the HAART-x-resistant HIV-1 disease (or Mega-HAART-x- resistant HIV-1 virus), by means of preventing its emergence. Each one antiretroviral drug and each HAART-x – or maybe Mega-HAART-x – regimen divides the actual HIV-1 viral population in : A single. drug-sensitive-virus (DSV) , which is killed off by HAART-x or Mega-HAART-x respectively, and 2. drug-resistant-virus(DRV), whose breakthrough can be prevented by the multivalent-polyvalent healing vaccine (MPTV -x) which is pre-administrated to its related HAART-x regimen or Mega-HAART-x regimen, correspondingly. If a pre – HAART-x administrated multivalent-polyvalent therapeutic vaccine (MPTV -x) manages to prevent the emergence associated with drug-resistant-virus(DRV), HIV-1 can be eradicated , since the following HAART-x-regimen will eliminate the drug-sensitive- virus(DSV). Benefits : Infection and immunity are generally two sides of the same silver coin. Therefore it is reasonable and methodically sound to vaccinate an HIV-1 constructive person with killed HIV-1 virus resistant to a specific HAART-x regimen, before HAART-x treatment ; and with killed wild-type HIV-1 (eventually collected from the patients’ blood before HAART-x treatments onset) at the end of just about all HAART-x or Mega-HAART-x therapies, especially when a long-term structured -treatment – interruption (STI) is definitely planned or intended. This particular vaccination with whole, killed, wild-type HIV-1 virus should be done shortly before HAART-x or maybe Mega-HAART-x therapy is stopped ( or disturbed ), since it is well known that quite a few wild-type HIV-1 may still be hidden in some organs or tissue reservoirs and since it is also well-known that at some point surviving HAART-resistant- HIV-1 virus tends to go back to wild-type HIV-1 virus , after HAART-treatment will be stopped. Two Latin quotes describe the rationale of using (MPTV -x, HAART-x)-couples and (MPTV-x,Mega-HAART-x)-couples in eradication of HIV-1. “Divide et Impera” flawlessly describes the role and also action of HAART-x and Mega-HAART-x programs, which divide the HIV-1 viral population in drug-sensitive-virus(DSV), which is eliminated/cleared by simply HAART-x and Mega-HAART-x -regimens respectively, and drug-resistant-virus(DRV) , whoever emergence is prevented by the multivalent-polyvalent therapeutic vaccine (MPTV -x) which is pre-administrated to HAART-x and also Mega-HAART-x respectively, according to the main rule of prevention, vaccination and homeopathy “Similia Similibus Curentur”. The actual golden standard for multivalent-polyvalent beneficial vaccines (MPTV-x)-s to be used in (MPTV -x, HAART-x)-couples or perhaps (MPTV -x,Mega-HAART-x)-couples, should be whole , killed HIV-1 malware or whole, highly inactivated HIV-1 malware (e.g. Remune-like and Remune-RMP-x- changed), bearing on its genome blueprint the resistance-mutations-pattern(s) (RMP-x-s), that would be generated through the following, to come HAART-x-regimen. On the other hand, the supreme aim of pathogen (HIV-1) -genome sequencing is the progression of vaccines. The genome sequence will be the”parts list”, and each gene or gene product ought to be tested for its potential convenience in anti-HIV-1 vaccine and therapeutic vaccine growth. The process of HIV-1 eradication may be split in 3 steps by way of monitoring HIV-1 viral load minimizes : STEP 1 would mean a virus-like load decrease from 61.000copies/ml or highr to 5-50 copies/ml; STEP 2 would mean a viral load reduce from 5-50 copies/ml to 5-50 copies/litre and STEP 3 would mean a further viral heap decrease from 5-50 copies/litre to actually zero copies/litre, i.e. eradication regarding HIV-1. Current HAART and Mega-HAART-x regimens make STEP1 possible for prolonged periods of time. Step # 2 and STEP 3 can only end up being accomplished by using (MPTV -x, HAART-x)-couples and/or (MPTV -x, Mega-HAART-x) -couples in set and / or cycles. (MPTV -x) , the multivalent-polyvalent beneficial vaccines, can be defined in addition to designed in many ways, depending on the drugs that are chosen as soulmates in the (MPTV -x, HAART-x)-couples and (MPTV-x,Mega-HAART-x)-couples. When a blend of reverse-transcriptase inhibitors (RTI-s) is chosen as a first-line pill – treatment,(MPTV -x) may contain at the very least 2 main components : 1. entire killed HIV-1 virus bearing a point-mutations (PM) of each reverse-transcriptase inhibitor properly their combination (Figure1/Table1) and 2. a good HIV-1 reverse-transcriptase enzyme bearing the point-mutations of the following, to come, to be used reverse-transcriptase inhibitors (RTI-s). If a combination of protease inhibitors is chosen, ,(MPTV-x) can also have 2 main components: A person. whole killed HIV-1 virus having the point-mutations (PM) of each protease inhibitor and of their combination(Figure1/Table1) and 2. an HIV-1 protease enzyme bearing a point-mutations (PM) that would be induced by way of the following, to come protease inhibitors (PI-s) in the absence of pre-administrated MPTV -x. If a combination of reverse-transcriptase and protease – inhibitors is chosen as the HAART-x component of a (MPTV-x, HAART-x)-couple, MPTV -x may contain at least 3 primary elements : 1. whole killed inactivated HIV-1 virus bearing the point-mutations (PM) of each reverse-transcriptase and of each protease chemical (Figure1/Table1), as well as the point-mutations (PM) with additional effect; 2.an HIV-1 reverse-transcriptase bearing the point-mutations (PM) that would be induced by way of the reverse-transcriptase inhibitors (RTI-s) to come; 3. an HIV-1 protease enzyme, bearing the point-mutations (PM) that has to be induced by the following, ahead, to be used protease inhibitors. In addition to the reverse-transcriptase inhibitors (RTI-s) and protease inhibitors(PI-s), union inhibitors like T 20 as well as T-1249, and integrase inhibitors like S-1360 and L870,810 (8) may be soon added to recent HAART-x and Mega-HAART-x regimens. ( The integrase enzyme is essential for HIV to integrate its proviral DNA in to the host cell chromosome. S-1360 ,e.gary the gadget guy., , is a low molecular weight chemical, for oral use, in which inhibits the integrase enzyme inside HIV-1.) An HIV-1 integrase- enzyme, bearing the actual point-mutations (PM), that would be induced around HIV-1-s genome by integrase inhibitors (II), may be launched as a fourth component of the multivalent-polyvalent therapeutic vaccine (MPTV -x) against HIV-1, along with : A person. whole killed/inactivated HIV-1 virus bearing the point-mutations (PM) of each reverse-transcriptase inhibitor, of each one protease inhibitor (Figure1/Table1), and of each integrase inhibitor , as well as the point-mutations (PM) with additional consequence; 2. An HIV-1 reverse-transcriptase bearing a point-mutations (PM) , RMS/RML -s that would be induced with the reverse-transcriptase- inibitors (RTI-s) to come; 3.An HIV-1 protease showing the point-mutations(PM) ,RMS/RML, and even the full RMP that would be induced by the right after, to come protease inhibitors. Most importantly in this article , the multivalent-polyvalent therapeutic vaccines (MPTV -x) may be explained and consist minimally of 3 digestive support enzymes : 1. an HIV-1 reverse-transcriptase enzyme, Two. an HIV-1 protease enzyme and 3. an HIV-1 integrase enzyme , each of the 3 minerals bearing the point-mutations (PM), resistance-mutations-loci (RML-x), resistance-mutations-sites (RMS-x) or perhaps the entire resistance-mutations-patterns (RMP-x-s) of the following , to come HAART-x regimen or Mega-HAART-x regimen, respectively. The rationale to use the 3 virus-like enzymes : reverse-transcriptase, protease and integrase as elements of a multivalent-polyvalent therapeutic vaccine (MPTV -x) against HIV-1 is founded on the fact that all currently authorized antiretroviral drugs are either reverse-transcriptase inhibitors, or protease inhibitors or perhaps integrase inhibitors, and only these drugs are competent to generate HIV-1 strains bearing on their genomes the point-mutations(PM), resistance-mutations-loci (RML-x), resistance-mutations-sites (RMS-x), resistance-mutations-patterns (RMP-x-s) listed in Table1/Figure1. Conversation : This entirely new strategy to treat HIV-1 infections with (MPTV -x, HAART-x)-couples and also (MPTV-x,Mega-HAART-x)-couples, can be adapted and familiar with treat all possible tricky – to – treat infectious diseases for which more then one effective drug has been formulated, and may lead to the eradication of numerous (otherwise resistant) microbes, pathogenic agents, viruses and fungi from your body of infected persons. Especially hard- to- treat infectious conditions, like tuberculosis (TB) and malaria , can be eradicated and drug-resistant pathogens eradicated when (MPTV -x, drugs-x ) -couples are carefully as well as wisely selected and applied rationally. This (MPTV -x, HAART-x)-couple-approach may also be used in the treating cancer. In cancer, this role of the MPTV -x can be used by killed cancer tissues bearing on their DNA the mutation-points(PM) of the anti-cancer drugs to use in chemotherapy. Conclusions : A large industry of multivalent therapeutic vaccinations (MTV-x), polivalent therapeutic vaccines (PTV-x), and, needless to say, multivalent-polyvalent therapeutic vaccines (MPTV-x)-s against HIV-1 will likely emerge after the publication i have told. These multivalent-polyvalent therapeutic vaccines (MPTV-x)-s might be used together with their affiliated HAART-x and Mega-HAART-x regimens in (MPTV -x,HAART-x)-couples in addition to (MPTV -x,Mega-HAART-x)-couples, respectively, Using an “ad conventium” terminology, a polivalent therapeutic vaccine (PTV-x) should have the capacity to avoid the emergence of the main resistance-mutations-pattern (RMP) for at least one antiretroviral drug or longer to a HAART or Mega-HAART -regimen. A multivalent restorative vaccine (MTV-x) should have the capacity to prevent your emergence of at least 2 successive resistance-mutations-patterns (RMP-s) for at least one drug, and up to a HAART or Mega-HAART -regimen, whereas a new multivalent-polyvalent therapeutic vaccine (MPTV -x) should be able to prevent the appearance of primary , secondary and perhaps multiple successive HIV-1 resistance-mutations-patterns (RMP-s) for a HAART or even Mega-HAART – regimen. Ideally, your multivalent-polyvalent therapeutic vaccine (MPTV -x) should be able to prevent the breakthrough of a very high or even endless number of successive resistance-mutations-patterns (RMP-s) and/or it should be have the ability eradicate HIV-1 by acting sinergetically making use of their corresponding HAART-x or Mega-HAART-x regimens, inside of these (MPTV -x, HAART-x)-couples, or (MPTV-x, Mega-HAART-x)-couples, respectively. ADVENTRX Pharmaceuticals intends to begin human studies for EradicAide (8) , an HIV therapeutic vaccine, composed of six synthetic peptides, which stimulate a new killer T-cell response to clear HIV-infected cellular material. A unique feature of this therapy for this is that it is designed to not solicit an antibody response. It is antibody-negative. This type of therapeutic vaccine may also be added to (MPTV -x, HAART-x)-couples as well as (MPTV-x,Mega-HAART-x)-couples , as an adjuvant therapeutic vaccine(ATV) to be able to (MPTV -x, HAART-x)-couples and (MPTV-x,Mega-HAART-x)-couples, respectively. Also, the Remune vaccine of the The Immune Response Corporation, Inc. (9) could possibly be considered ( and used ) being an adjuvant therapeutic vaccine(ATV) to (MPTV -x, HAART-x)-couples as well as (MPTV-x,Mega-HAART-x)-couples . Studies have shown that inactivated, gp120-depleted whole virus immunogen (Remune) boosts immune responses to HIV-1. Both therapeutic vaccines (Television for computer) mentioned above , (EradicAide and Remune), as well as others that happen to be in advanced development plus clinical trials, may eventually be modified, modified and adapted to use in one formulation prior to HAART-x (or perhaps Mega-Haart-x) onset, and in a different method during HAART-x or Mega-Haart-x treatment. Put simply, they may be used both in (MPTV -x, HAART-x)-couples in addition to (MPTV-x,Mega-HAART-x)-couples , and/or as adjuvant therapeutic vaccines(All terrain vehicle). Affymetrix (10) , a leading US firm in DNA-chip technology has developed GeneChip oligonucleotide probe arrays which might be manufactured using a high resolution photolitographic fabrication process adapted from the semiconductor industry, for HIV-1 mutations determinations. The Authors of this article believe that an entire market of standardized multivalent-polyvalent therapeutic vaccinations (SMPTV-x)-s will emerge, to act contributory and sinergetically with HAART-x and/or Mega-HAART-x – regimens in order to eradicate HIV-1. The Experts of this article are very interested to collaborate with pharmaceutical companies interested to produce (SMPTV -x)-s for use with (MPTV -x, HAART-x) -couples and (MPTV -x , Mega-HAART-x)-couples aimed and designed to eradicate HIV-1, cancer (11) , along with infectious diseases. References: A single. Hahn B.H. , Robertson D.D. , McCutchan F.E. , Sharp S.M. , Recombination and diversity connected with HIV: implications for vaccine improvement. Neuvieme Colloque Des Cent Gardes , 1994, 87-94 ; 2. Robertson N.L. , Sharp P.T. , McCutchan F.E. , Hahn B.L. , Recombination in HIV-1, Nature 1995 : 374 :124-126; A few. Robertson D.L. , Hahn B.M. , Sharp P.M. , Recombination within Aids viruses, J.Mol.Progress , 1995, 40, 249-259; 4. Sharpened P.M., Robertson D.R., Hahn B.H. , Cross ( space ) species transmission and recombination associated with ‘ AIDS ‘ worms. , Phil. Trans. R. Soc., London B , 1995, 349 : 41-47; 5. M. L. Kalish et , Recombinant Viruses and Early Worldwide HIV-1 Epidemic, Emerging Infectious Diseases, Vol.10, No.7, Come early july 2004; 6. I.Azines. Secasan, D.I. Pop , Preventing HIV with HIV, Medical Hypotheses,1998 Jan;40(1):39-42 Churchill-Livingstone, ISSN 0306-9877; 7. Young, Azines.D., et al. L870,810: Discovery of an potent HIV integrase inhibitor with potential clinical utility, Offered at The XIV International AIDS, Convention, Barcelona, Spain. 8. http://www.adventrx.com/products/antiv_eradicaide.htm On the lookout for. http://www.imnr.com : The Immune Result Corporation, Inc. web-site 10. http://www.affymetrix.com/index.affx Eleven. Iosif Secasan, Dan I. Pop, Ciprian C. Secasan: Potentially New And Imaginative Treatments For Superficial, Muscle-Invasive, And Metastatic Transition Cell Carcinoma (TCC) Of The Bladder. Online Journal of Oncology. 2005. Size 2 Number 2.